Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma

Autor: Salih Demir, Alina Hotes, Tanja Schmid, Stefano Cairo, Emilie Indersie, Claudio Pisano, Eiso Hiyama, Tomoro Hishiki, Christian Vokuhl, Sophie Branchereau, Penelope Brock, Irene Schmid, József Zsiros, Roland Kappler

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)

Abstract Background Patients with metastatic hepatoblastoma are treated with severely toxic first-line chemotherapies in combination with surgery. Yet, inadequate response of lung metastases to neo-adjuvant chemotherapy still compromises patient outc

Externí odkaz: https://doaj.org/article/53a8ce2fffa04f4e80b7ddc784aea505

Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring during Childhood Cancer Treatment

Autor: Bruce Carleton, Richard J. Cohn, Stefan Rutkowski, Eric Bouffet, Wendy Landier, Mariana Kruger, David R. Freyer, Vassilios Papadakis, Gabriele Calaminus, Antoinette am Zehnhoff-Dinnesen, Lillian Sung, Marry M. van den Heuvel-Eibrink, James I. Geller, Kaukab Rajput, Claudia Blattmann, Kay W. Chang, Jennifer H Foster, Kristin Knight, Alexander E Hoetink, A Meijer, Hiske W Helleman, Beth Brooks, Penelope Brock, Godelieve A.M. Tytgat, Lisa L. Hunter, Martine van Grotel, Rachael Windsor, Bruce Morland, A. Lindsay Frazier, Barbara Hero

Publikováno v: JAMA Oncology.

Importance Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part of the supportive care pathway enables early detection of hearing loss, decision-making about ongo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202bd7b5615ff098036a75a61221dab1
https://doi.org/10.1001/jamaoncol.2021.2697

New insights into cisplatin ototoxicity

Autor: Penelope Brock

Publikováno v: CancerReferences. 128(1)

LAY SUMMARY Platinum-containing chemotherapy is often used to treat children with cancer. Although it is a very effective medication, unfortunately, it causes permanent hearing loss in more than one-half of the children who receive it. In this issue

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5928f26e2b91612ea9d4b237909d21f3
https://pubmed.ncbi.nlm.nih.gov/34490624

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Autor: Ulrike Pötschger, Hans Loibner, Holger N. Lode, Shifra Ash, Godfrey Chi-Fung Chan, Penelope Brock, Alberto Garaventa, Dominique Valteau-Couanet, Victoria Castel, Ruth Ladenstein, Andrew D.J. Pearson, Guenter Schreier, Jean Michon, Toby Trahair, Ellen Ruud, Genevieve Laureys, Peter F. Ambros, Maja Beck-Popovic, Henrik Schroeder, Roberto Luksch, Cormac Owens, Maria Rita Castellani, Keith Holmes, Mark N. Gaze

Publikováno v: Cancers, Vol 12, Iss 2, p 309 (2020)
Cancers
Volume 12
Issue 2
Ladenstein, R, Pötschgerulrike.poetschger@ccri.at, U, Valteau-couanet, D, Luksch, R, Castel, V, Ash, S, Laureys, G, Brock, P, Michon, J M, Owenscormac.owens@olchc.ie, C, Trahair, T, Chan, G C F, Ruud, E, Schroeder, H, Beck-popovic, M, Schreier, G, Loibner, H, Ambros, P, Holmes, K, Castellani, M R, Gaze, M N, Garaventa, A, Pearson, A D J & Lode, H N 2020, ' Investigation of the role of dinutuximab beta-based immunotherapy in the siopen high-risk neuroblastoma 1 trial (HR-NBL1) ', Cancers, vol. 12, no. 2, 309 . https://doi.org/10.3390/cancers12020309
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c473380705672f3226abb700809e06d2
https://www.mdpi.com/2072-6694/12/2/309

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group

Autor: Peter F. Ambros, Michelle Haber, Frank Berthold, Hiroyuki Shimada, Julie R. Park, Susan A. Burchill, Robert C. Seeger, Godelieve A.M. Tytgat, Penelope Brock, Klaus Beiske

Publikováno v: Cancer. 123:1095-1105

BACKGROUND: The current study was conducted to expedite international standardized reporting of bone marrow disease in children with neuroblastoma and to improve equivalence of care. METHODS: A multidisciplinary International Neuroblastoma Response C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb232b4b9b099205e26c0d016860f638
https://doi.org/10.1002/cncr.30380